Latest News for SANN.SW
Ad-hoc-Mitteilung gemäss Art. 53 KR. Pratteln, Schweiz, 30. April 2026 - Santhera Pharmaceuticals (SIX: SANN) schlägt vor, Dr. Srishti Gupta, MD, MPP, MPhil, auf der bevorstehenden ordentlichen Generalversammlung am 26.
Ad hoc announcement pursuant to Art. 53 LR. Pratteln, Switzerland, April 30, 2026 - Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Srishti Gupta, MD, MPP, MPhil, as an Independent Director at the upcoming Annual General Meeting to be held on May 26, 2026.
With eBay Inc (NASDAQ:EBAY, XETRA:EBA) set to report its first-quarter 2026 results on April 29, UBS has bumped its price target on the stock to $110 from...
Pratteln, Schweiz, 27. April 2026 - Santhera Pharmaceuticals (SIX: SANN) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur (EMA) eine positive Stellungnahme abgegeben hat, in der eine Erweiterung der Zulassung für AGAMREE (Vamorolon) auf die Behandlung von Patienten mit Duchenne-Muskeldystrophie (DMD) ab einem Alter von 2 Jahren empfohlen wird.
Pratteln, Switzerland, April 27, 2026 - Santhera Pharmaceuticals (SIX: SANN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an extension to the marketing authorization for AGAMREE (vamorolone) to include the treatment of patients with Duchenne muscular dystrophy (DMD) from 2 years of age.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SANN.SW.
Senate Trading
No Senate trades found for SANN.SW.
U.S. House Trading
No House trades found for SANN.SW.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.